US FDA allows companies to distribute articles on off-label use - Update
This article was originally published in SRA
The US Food and Drug Administration has finalised controversial guidance that permits medical device and drug manufacturers to disseminate information to healthcare professionals on the off-label uses of their approved products by reprinting articles in medical and scientific journals1,2. The document contains recommendations outlining the approach that the agency wants companies to follow in printing and distributing such articles.
You may also be interested in...
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.